Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,590,725
  • Shares Outstanding, K 221,505
  • Annual Sales, $ 2,986 M
  • Annual Income, $ 948,580 K
  • 60-Month Beta 0.71
  • Price/Sales 5.60
  • Price/Cash Flow 31.75
  • Price/Book 4.33
Trade INCY with:

Options Overview Details

View History
  • Implied Volatility 39.39% ( -2.86%)
  • Historical Volatility 34.39%
  • IV Percentile 61%
  • IV Rank 25.28%
  • IV High 74.34% on 11/29/21
  • IV Low 27.56% on 08/06/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 66
  • Volume Avg (30-Day) 122
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 18,604
  • Open Int (30-Day) 18,485

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.61
  • Number of Estimates 6
  • High Estimate 0.72
  • Low Estimate 0.47
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -6.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.35 +3.52%
on 05/09/22
82.85 -9.60%
on 04/14/22
-7.09 (-8.65%)
since 04/13/22
3-Month
65.60 +14.18%
on 02/14/22
84.86 -11.74%
on 04/08/22
+8.14 (+12.19%)
since 02/11/22
52-Week
61.91 +20.98%
on 11/02/21
88.26 -15.14%
on 06/28/21
-8.33 (-10.01%)
since 05/13/21

Most Recent Stories

More News
3 Buy-Rated Biotechs to Buy in May

Despite logistical hurdles, the biotech industry is expected to expand solidly in the coming years on lucrative federal investments and strong demand. Therefore, we think it could be wise to bet on the...

BIIB : 199.11 (+2.47%)
BNTX : 158.84 (+0.53%)
INCY : 74.90 (-0.81%)
Why CTI Biopharma Stock Is Surging Today

A strong launch for the company's first commercialized drug drew a cheer from investors.

CTIC : 4.20 (+14.75%)
INCY : 74.90 (-0.81%)
Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID

The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.

PFE : 49.92 (-0.93%)
LLY : 291.63 (-0.06%)
INCY : 74.90 (-0.81%)
ABBV : 153.50 (-0.51%)
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced the European Commission (EC) has approved Jakavi ® (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate...

INCY : 74.90 (-0.81%)
Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 2022 RBC Capital Markets Healthcare Conference on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.

INCY : 74.90 (-0.81%)
Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates

Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

NVS : 85.82 (+0.52%)
LLY : 291.63 (-0.06%)
VRTX : 246.72 (+2.44%)
INCY : 74.90 (-0.81%)
Incyte (INCY) Lags Q1 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

INCY : 74.90 (-0.81%)
NTLA : 48.60 (+14.08%)
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

INCY : 74.90 (-0.81%)
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

BIIB : 199.11 (+2.47%)
PFE : 49.92 (-0.93%)
TEVA : 7.76 (+3.33%)
INCY : 74.90 (-0.81%)
ESPR : 5.78 (+10.31%)
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib...

INCY : 74.90 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

3rd Resistance Point 78.31
2nd Resistance Point 77.46
1st Resistance Point 76.18
Last Price 74.90
1st Support Level 74.05
2nd Support Level 73.21
3rd Support Level 71.93

See More

52-Week High 88.26
Fibonacci 61.8% 78.19
Fibonacci 50% 75.08
Last Price 74.90
Fibonacci 38.2% 71.98
52-Week Low 61.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar